PD-1抗体联合抗血管生成靶向治疗在晚期复发转移头颈部肿瘤中的探索研究

doi:10.13701/j.cnki.kqyxyj.2020.02.016

口腔医学研究 ›› 2020, Vol. 36 ›› Issue (2): 158-163.DOI: 10.13701/j.cnki.kqyxyj.2020.02.016

PD-1抗体联合抗血管生成靶向治疗在晚期复发转移头颈部肿瘤中的探索研究

李艺, 窦圣金, 张霖, 李烿烿, 朱国培^*

上海交通大学医学院附属第九人民医院,口腔医学院,口腔-颌面头颈肿瘤科上海 200011

收稿日期:2019-06-11 出版日期:2020-02-28 发布日期:2020-04-24
通讯作者: 朱国培,E-mail:antica@gmail.com
作者简介:李艺(1988~ ),男,扬州人,硕士,主治医师,主要研究方向头颈部肿瘤的放射治疗。

Exploration and Study of PD-1 Antibody Combined with Anti-angiogenesis Targeted Therapy in Advanced Recurrent and Metastatic Head and Neck Tumors

LI Yi, DOU Shengjin, ZHANG Lin, LI Rongrong, ZHU Guopei^*

Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received:2019-06-11 Online:2020-02-28 Published:2020-04-24

摘要/Abstract

摘要： 目的:观察PD-1抗体联合抗血管靶向治疗在晚期复发转移头颈部肿瘤中的疗效和耐受情况。方法:回顾性分析使用PD-1单抗抗体联合抗血管靶向治疗的4例晚期复发转移头颈部肿瘤患者的临床资料,采用RECIST 1.1标准评价4例患者的疗效,并观察其治疗的耐受情况。结果:使用PD-1单抗抗体联合抗血管靶向治疗的4例患者1例达CR,1例达PR,1例虽SD但病灶缩小,症状缓解,1例PD,用药期间均未出现有出血现象,患者对治疗的总体耐受性良好,未出现明显的3~4级不良反应。结论:PD-1抗体联合抗血管靶向治疗是晚期复发转移头颈部肿瘤治疗的新选择,且耐受性良好。

关键词: 抗PD-1抗体, 阿帕替尼, 晚期复发转移, 头颈部肿瘤

Abstract: Objective: To observe the efficacy and tolerance of PD-1 antibody combined with anti-vascularized targeted therapy in advanced recurrent metastatic head and neck tumors. Methods: The clinical data of 4 patients with advanced recurrence and metastatic head and neck tumors treated with PD-1 monoclonal antibody combined with anti-vascular targeted therapy were retrospectively analyzed. RECIST 1.1 was used to evaluate the efficacy of 4 patients and observe their tolerance to treatment. Results: In the 4 patients treated with PD-1 monoclonal antibody combined with anti-vessel targeted therapy, 1 patient achieved CR, 1 patient achieved PR, 1 patient showed focal shrinkage and symptom relief despite SD, and 1 patient showed PD. No bleeding occurred during the medication, and the overall tolerance of the patients to the treatment was good, with no significant grade 3-4 adverse reactions. Conclusion: PD-1 antibody combined with anti-vascular targeted therapy is a new choice for the treatment of head and neck tumors with advanced recurrence and metastasis, and it is well tolerated.

Key words: anti-PD-1 antibody, Apatinib, advanced recurrence and metastasis, head and neck tumor

李艺, 窦圣金, 张霖, 李烿烿, 朱国培. PD-1抗体联合抗血管生成靶向治疗在晚期复发转移头颈部肿瘤中的探索研究[J]. 口腔医学研究, 2020, 36(2): 158-163.

LI Yi, DOU Shengjin, ZHANG Lin, LI Rongrong, ZHU Guopei. Exploration and Study of PD-1 Antibody Combined with Anti-angiogenesis Targeted Therapy in Advanced Recurrent and Metastatic Head and Neck Tumors[J]. Journal of Oral Science Research, 2020, 36(2): 158-163.

参考文献

[1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917.
[2] Martinez-Useros J, Garcia-Foncillas J. The chanllenge of blocking a wider family member of EGFR against head and neck squamous cell carcinomas[J]. Oral Oncol, 2015, 51(5):423-430.
[3] Allen CT, Judd NP, Bui JD, et al. The clinical implications of antitumor immunity in head and neck cancer[J]. Laryngoscope, 2012, 122(1): 144-157.
[4] Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma[J]. Cancer Res, 2001, 61(15): 5911-5918.
[5] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase Ib trial[J]. Lancet Oncol, 2016, 17(7): 956-965.
[6] Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phaseⅠb KEYNOTE-012 expansion cohort[J]. J Clin Oncol, 2016, 34(32): 3838-3845.
[7] Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study[J]. J Clin Oncol, 2017, 35(14): 1542-1549.
[8] Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard,single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck(CheckMate 141):health-related quality-of-life results from a randomized,phase 3 trial [J]. Lancet Oncol, 2017, 18:1104.
[9] Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential [J]. Cell, 2015, 161(2):205-214.
[10] Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression an a more favorable tumor microenvironment in patients with metastatic melanoma [J]. Clin Cancer Res an Offi J Am Associ Cancer Res, 2013, 19(5):1225-1231.
[11] McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma [J]. Nat Med, 2018, 24(6):749-757.

PD-1抗体联合抗血管生成靶向治疗在晚期复发转移头颈部肿瘤中的探索研究

Exploration and Study of PD-1 Antibody Combined with Anti-angiogenesis Targeted Therapy in Advanced Recurrent and Metastatic Head and Neck Tumors

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics